Loading...
XSHE
002898
Market cap173mUSD
Apr 11, Last price  
7.18CNY
1D
-0.69%
1Q
-21.27%
IPO
-38.76%
Name

Sailong Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
P/E
132.55
P/S
4.07
EPS
0.05
Div Yield, %
0.28%
Shrs. gr., 5y
-0.01%
Rev. gr., 5y
-6.57%
Revenues
311m
+17.58%
221,342,112178,093,561237,495,042255,836,805364,218,632436,272,811293,466,984120,684,285247,078,587264,192,655310,627,026
Net income
10m
45,877,10428,190,78163,317,85961,248,72864,505,08360,904,85127,483,2100009,533,684
CFO
36m
+152.80%
64,842,30051,362,90247,438,79078,653,07785,126,4313,328,4690174,69035,461,28414,124,68535,706,967
Dividend
Jun 28, 20240.02 CNY/sh
Earnings
May 16, 2025

Profile

Sailong Pharmaceutical Group Co., Ltd. researches, develops, produces, markets, and services pharmaceutical intermediates, raw materials, and preparations in China. The company offers esomeprazole sodium, ornithine aspartate, thymus, argatroban, gaicycline, monosialotetrahexose ganglioside sodium, cerebroprotein hydrolysate, milrinone, parecoxib sodium, tranexamic acid, clindamycin phosphate, and pantoprazole sodium products. It provides its products for therapeutic areas, such as cardiovascular, cerebrovascular, nerve, digestive system, proton pump inhibitors, anti-infectives, anti-bleeding medicine, analgesics, and other fields. The company was formerly known as Zhuhai Sailong Pharmaceutical Co.,Ltd. and changed its name to Sailong Pharmaceutical Group Co., Ltd. in September 2021. Sailong Pharmaceutical Group Co., Ltd. was founded in 2002 and is based in Zhuhai, China.
URL
http://www.sailong.cn
IPO date
Sep 12, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
310,627
17.58%
264,193
6.93%
Cost of revenue
273,248
258,858
Unusual Expense (Income)
NOPBT
37,379
5,334
NOPBT Margin
12.03%
2.02%
Operating Taxes
12,823
7,642
Tax Rate
34.30%
143.25%
NOPAT
24,557
(2,307)
Net income
9,534
 
Dividends
(5,579)
(8,695)
Dividend yield
0.23%
0.41%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
90,048
129,935
Long-term debt
25,156
13,679
Deferred revenue
2,842
3,084
Other long-term liabilities
13,232
Net debt
(43,915)
(8,459)
Cash flow
Cash from operating activities
35,707
14,125
CAPEX
(30,579)
Cash from investing activities
(19,325)
Cash from financing activities
FCF
42,948
32,595
Balance
Cash
89,262
72,270
Long term investments
69,856
79,803
Excess cash
143,587
138,864
Stockholders' equity
265,422
237,879
Invested Capital
523,535
523,890
ROIC
4.69%
ROCE
5.52%
0.79%
EV
Common stock shares outstanding
175,898
176,000
Price
13.97
14.98%
12.15
16.27%
Market cap
2,457,298
14.91%
2,138,400
16.27%
EV
2,431,393
2,129,941
EBITDA
70,511
39,396
EV/EBITDA
34.48
54.06
Interest
6,907
8,085
Interest/NOPBT
18.48%
151.55%